Literature DB >> 23146437

Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles.

Jianan Shen1, Huiping Sun, Pengfei Xu, Qi Yin, Zhiwen Zhang, Siling Wang, Haijun Yu, Yaping Li.   

Abstract

The metastasis of breast cancer is the leading cause of cancer death in women, and the lung is a common location of a secondary tumor that has metastasized from the primary source tumor. In this work, an attempt to simultaneously inhibit the metastasis and growth of tumor by co-delivering Twist shRNA (shTwi) and paclitaxel (PTX) using the conjugate of pluronic P85 (P85) and low molecular weight polyethyleneimine (PEI) (P85-PEI)/D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) complex nanoparticles (PTPNs) was performed on metastatic 4T1 breast cancer cell line and its pulmonary metastasis mice model. The experimental results demonstrated that PTPNs could effectively achieve cellular uptake and RNA interference. The down-regulation of Twist protein resulted in significant inhibitory effect of cell migration and invasion with the inhibition rate of 88.7% and 91.06%, respectively. The IC₅₀ of PTPNs against 4T1 cells was 63-fold lower than that of free PTX. The prolonged circulation and increased accumulation of PTX and shTwi in lung and tumor were observed in in vivo biodistribution. The in vivo antitumor efficacy showed that PTPNs could not only inhibit the in situ tumor growth effectively, but also completely restrict the pulmonary metastasis in 4T1 pulmonary metastatic mice model. Therefore, co-delivering chemotherapy drugs with metastasis regulator by PTPNs to simultaneously inhibit metastasis and growth of tumor could achieve synergistic effect for the effective therapy of metastatic breast cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146437     DOI: 10.1016/j.biomaterials.2012.10.057

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  10 in total

Review 1.  Nanoparticulate RNA delivery systems in cancer.

Authors:  Ankur Sharma; Niraj Kumar Jha; Kajal Dahiya; Vivek Kumar Singh; Kundan Chaurasiya; Aditya Narayan Jha; Saurabh Kumar Jha; Prabhu Chandra Mishra; Sunny Dholpuria; Rani Astya; Parma Nand; Amit Kumar; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-30

2.  Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

Authors:  G Salzano; R Riehle; G Navarro; F Perche; G De Rosa; V P Torchilin
Journal:  Cancer Lett       Date:  2013-10-04       Impact factor: 8.679

Review 3.  Development of individualized anti-metastasis strategies by engineering nanomedicines.

Authors:  Qianjun He; Shengrong Guo; Zhiyong Qian; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2015-06-09       Impact factor: 54.564

4.  Nanoparticle-based targeted gene therapy for lung cancer.

Authors:  Hung-Yen Lee; Kamal A Mohammed; Najmunnisa Nasreen
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

Review 5.  The role of TWIST1 in epithelial-mesenchymal transition and cancers.

Authors:  Qing-Qing Zhu; Chenhui Ma; Qian Wang; Yong Song; Tangfeng Lv
Journal:  Tumour Biol       Date:  2015-11-24

Review 6.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

Review 7.  Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy.

Authors:  Songwei Tan; Chenming Zou; Wei Zhang; Mingxing Yin; Xueqin Gao; Qing Tang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Tumor Microenvironment Targeted Nanotherapy.

Authors:  Clara Fernandes; Divya Suares; Mayur C Yergeri
Journal:  Front Pharmacol       Date:  2018-10-31       Impact factor: 5.810

Review 9.  Nanomaterials as Inhibitors of Epithelial Mesenchymal Transition in Cancer Treatment.

Authors:  Marco Cordani; Raffaele Strippoli; Álvaro Somoza
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

10.  Synergistic inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein/DOX nanodispersions.

Authors:  Ruoning Wang; Yujie Yang; Mengmeng Yang; Dandan Yuan; Jinyu Huang; Rui Chen; Honglan Wang; Lihong Hu; Liuqing Di; Junsong Li
Journal:  J Nanobiotechnology       Date:  2020-08-26       Impact factor: 10.435

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.